

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jason Gray  
Serial No.: 10/561,009  
Confirmation No.: 6040  
Filed: June 21, 2007  
For: AMORPHOUS FORM OF OLANZAPINE  
Examiner: Brenda Libby Coleman  
Art Unit: 1624

---

**CERTIFICATE OF ELECTRONIC FILING UNDER 37 C.F.R. § 1.8**

The undersigned hereby certifies that this paper, along with any paper referred to as being attached or 8th day of October, 2010.

/Lucie DeBellis/

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. § 1.97**

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of a first Office Action, but before the mailing date of any of a Final Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in this application. Therefore, please charge our credit card in the amount of \$180.00 covering the fee set forth in 37 C.F.R. § 1.17(p).

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The above-identified U.S. application claims priority to international PCT application No. PCT/GB2004/02579. If the Examiner has not had the benefit of review of the file history of PCT/GB2004/02579, then he/she is asked to contact the undersigned, who will provide a copy of same.

The Applicant would also like to bring to the Examiner's attention the enclosed search reports or other communications from a corresponding or related international or foreign patent application:

<b>Serial No.</b>	<b>Date of Mailing</b>	<b>Type(s) of Communication</b>
PCT/GB2004/002579	October 27, 2004	International Search Report and Written Opinion
PCT/GB2004/002579	January 5, 2006	International Preliminary Report on Patentability

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The non-patent literature reference, entitled "Remington: The Science and practice of pharmacy," was first cited in an Information Disclosure Statement filed August 17, 2010 with the incorrect page number. Therefore, Applicant re-cites this reference herein with the correct page number. In addition, the Applicant submits herewith an additional copy of the reference.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

The Director is hereby authorized to charge any deficiency or credit any overpayment in the fees due to our Deposit Account No. 23/2825 under Docket No. V0005.70102US00 from which the undersigned is authorized to draw.

Respectfully submitted,

By: /C. Hunter Baker/  
C. Hunter Baker, M.D., Ph.D.  
Registration Number: 46,533  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: V0005.70102US00  
Date: October 8, 2010  
**xNDDx**